Table 2.
Key characteristics of participants at baseline in three trials that contributed individual participant data
| Characteristic | Aspirin group (N = 1188) |
Placebo group (N = 1118) |
|---|---|---|
| Age (years) | 60.1 (8.9) | 60.1 (8.6) |
| Male sex | 455 (38.3) | 433 (38.7) |
| Body mass index (kg/m2) | 28.8 (5.7) | 29.1 (6.0) |
| Systolic blood pressure (mmHg) | 134.8 (14.4) | 134.7 (13.8) |
| Total cholesterol (mmol/l)* | 5.66 (1.20) | 5.41 (1.16) |
| Smoking status | ||
| Other | 1015 (85.5) | 966 (86.5) |
| Current | 172 (14.5) | 151 (13.5) |
| History of hypertension | ||
| No | 469 (39.5) | 453 (40.7) |
| Yes | 718 (60.5) | 661 (59.3) |
| Baseline treatment for hypertension* | ||
| No | 489 (61.4) | 455 (61.6) |
| Yes | 307 (38.6) | 284 (38.4) |
| Family history of MI* | ||
| No | 666 (84.0) | 623 (84.2) |
| Yes | 127 (16.0) | 117 (15.8) |
| History of RA | ||
| No | 898 (98.4) | 842 (97.9) |
| Yes | 15 (1.6) | 18 (2.1) |
* Data contributed by two trials; values are mean (SD), median (IQR), or n (%); MI, myocardial infarction; rheumatoid arthritis